← 홈

혈액암 (AML/ALL)

858개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 858개
ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 80%임상시험 25상태 RECRUITING
CGTBiologicstaleNkarta, Inc.Phase 2

allogeneic, donor-derived NK cells (allogeneic, donor-derived NK cells)

Acute Myelogenous Leukemia · Acute Myelogenous Leukemia

#AcuteMyelogenousLeukemia#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 4%임상시험 25상태 DISCONTINUED
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Nemtabrutinib (Nemtabrutinib)

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0.0%임상시험 23상태 RECRUITING
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 3

zolbetuximab (zolbetuximab)

Gastric Cancer; Gastroesophageal Junction Adenocarcinoma · Locally Advanced Unresectable Gastroesop

#LocallyAdvancedUnresectableGastr#Antibody#Phase3#항체#면역항체+4
효능 ORR 48.1%임상시험 23상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

HER3-DXd (HER3-DXd)

Carcinoma, Non-Small-Cell Lung · HER3

#HER3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-1 Lyo-DP (HER3-DXd, HER3-DXd (CTM-1 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-3 Lyo-DP (HER3-DXd, HER3-DXd (CTM-3 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

Linvoseltamab (Linvoseltamab)

Food Allergy · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 23.9%임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab [KEYTRUDA®])

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · Metastatic Cancer

#MetastaticCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 40%임상시험 22상태 DISCONTINUED
AntibodystaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+4
효능 ORR 75%임상시험 20상태 RECRUITING
CGTBiologicstaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#세포유전치료#CAR-T+4
효능 ORR 92.9%임상시험 20상태 ACTIVE
AntibodystaleEli LillyPhase 2

Cetuximab + Gemcitabine + Oxaliplatin (Cetuximab + Gemcitabine + Oxaliplatin)

Cholangiocarcinoma; Adenocarcinoma of Gallbladder · Unresectable

#Unresectable#Antibody#Phase2#항체#면역항체+4
효능 ORR 5%임상시험 19상태 ACTIVE
ADCBiologicstaleEli Lilly and CompanyPhase 2

Olutasidenib (Olutasidenib)

Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 2%임상시험 19상태 RECRUITING
ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+3
효능 ORR 71.7%임상시험 19상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING

10 / 43 페이지

← 이전다음 →